ClinPharm Consulting Forms Strategic Partnership with NCE Biotech
Research Triangle Park, N.C.
Early phase drug development consulting firm ClinPharm Consulting and 20-year pharmaceutical industry veteran Eric Nelson, Ph.D. have announced a partnership to expand upon their offerings for emerging pharmaceutical and biotechnology companies.
Dr. Nelson's firm, NCE Biotech, and ClinPharm Consulting will collaborate to offer an integrated suite of clinical pharmacology, R&D strategy, and business development services, enabling the firms to provide strategic advice related to optimizing drug development programs. This new service enables clients to build the best efficacy/safety and market profiles for their drug development programs for discussions with pharmaceutical company partners and potential investors.
ClinPharm Consulting offers a full clinical pharmacology development package to clients and is a complete resource for virtual companies seeking to advance early phase drug development programs. According to Dr. Banks, early phase drug development needs to be coordinated with business development activities in order to most effectively translate early discussions with potential pharma partners into workable R&D development plans.
NCE Biotech's services include consulting to large pharmaceutical companies to help them divest drug programs; finding Asian investor funding for U.S. biotechnology companies and universities; working with private equity groups to acquire idle biotech assets; and running virtual drug development teams.
"The new partnership with ClinPharm Consulting is a great fit for our firm as the combined team can now provide cost-effective, integrated drug development and business development advice to our clients", said Dr. Nelson, managing partner at NCE Biotech.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
